New Hope for Children's Vision: Targeting Mitochondrial Dysfunction in Eye Disease
Researchers at Boston Children's Hospital have identified a promising therapeutic target for Autosomal Dominant Optic Atrophy (ADOA), a common genetic condition causing progressive vision loss in children. The breakthrough focuses on disabling a protein called SARM1, which triggers nerve cell degeneration.
Key Takeaways
- A new study identifies SARM1 as a critical target for treating ADOA.
- Disabling SARM1 preserved retinal ganglion cells and vision in a mouse model.
- A drug designed to inhibit SARM1 is being evaluated for potential clinical trials.
- Early genetic diagnosis is crucial for identifying children who could benefit from future treatments.
Understanding Autosomal Dominant Optic Atrophy (ADOA)
ADOA is the most prevalent genetic optic neuropathy, characterized by a slow onset of symptoms during childhood. These can include blurry vision, difficulty with reading or focusing, and sometimes are only detected through failed vision tests. The underlying cause is the deterioration of retinal ganglion cells (RGCs), the neurons responsible for transmitting visual information to the brain. In most ADOA cases, mutations in the OPA1 gene disrupt mitochondrial function, which is essential for cellular energy production and overall cell health.
A Promising Therapeutic Target: SARM1
Led by Thomas Schwarz, Ph.D., and Chen Ding, Ph.D., the research team at the Schwarz Lab discovered that deactivating the SARM1 protein could protect RGCs and maintain vision. SARM1 is known to initiate axon degeneration, the breakdown of the signal-carrying parts of nerve cells. In ADOA, the activation of this process leads to damage in RGCs. "What we've found is a molecular off-switch of sorts for the process that causes these cells to die in the first place," explained Ding. By removing SARM1 in a mouse model with the OPA1 mutation, the researchers observed that RGCs remained functional, and the mice retained their vision.
From Discovery to Drug Development
Inspired by a family whose daughter is at risk for ADOA, the Schwarz Lab is now exploring therapeutic strategies to inhibit SARM1, rather than solely relying on genetic manipulation. With support from the family and a grant from Advancium Health Network, the team is evaluating ASHA-624, a novel drug designed to block SARM1 by locking it into an inactive state. This approach aims to prevent the triggering of axonal degeneration. "If the SARM1 inhibition we're testing in the lab now is effective, the next step will be to see if inhibiting it in patients can deliver the same nerve-protecting effects," Ding stated.
The Path Forward
Schwarz and Ding believe this research marks a pivotal moment for physicians and families affected by ADOA. As SARM1-targeted treatments progress towards clinical trials, they emphasize the critical importance of early genetic diagnosis. Identifying children at risk will allow for timely intervention, offering a genuine chance to preserve vision rather than merely slowing its inevitable loss. "SARM1 inhibition is a new way to think about ADOA," said Schwarz. "We hope that a therapy is within our reach, and we want to move it forward as fast as we can."
